Trials / Not Yet Recruiting
Not Yet RecruitingNCT02497898
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- The First People's Hospital of Changzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Detailed description
Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cytokine-induced killer cells (CIK) | Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2038-07-01
- Completion
- 2040-07-01
- First posted
- 2015-07-15
- Last updated
- 2015-07-15
Source: ClinicalTrials.gov record NCT02497898. Inclusion in this directory is not an endorsement.